N. Lakhani
2005
Citations
0
Influential Citations
3
Citations
Journal
Journal name not available for this finding
Abstract
EVALUATION OF THE PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP, METABOLISM & PLASMA PROTEIN BINDING OF THE NOVEL ANTITUMOR AGENT, 2-METHOXYESTRADIOL (2ME2), FOLLOWING ORAL ADMINISTRATION IN PATIENTS WITH SOLID TUMORS By Nehal J. Lakhani, M.B; B.S., Ph.D. A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. Virginia Commonwealth University, 2005 Major Director: Jurgen Venitz, M.D., Ph.D. Associate Professor and Vice Chairman, Department of Pharmaceutics Major Director: William D. Figg, Pharm.D., M.B.A. Head, Clinical Pharmacology Research Core & Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health The goal of this research was to determine safety, tolerability and pharmacokinetics of 2ME2 in patients with solid tumors and determine maximum tolerated dose (MTD). The following hypotheses were tested: 1) 2ME2 will be well tolerated in clinic when given orally and will have quantifiable effects on the ex vivo markers of angiogenesis and